It has a lot to do with being an orphan drug. Companies will not innovate, develop drugs and run costly trials for small markets if they cannot charge a large premium for those small markets. That’s how orphan drug pricing works. So yes, we could charge a fair bit higher for PPS for MPS versus PPS for OA and justifiably so.
Just IMO and DYOR.
Ann: Paradigm AGM Presentation, page-37
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.010(4.00%) |
Mkt cap ! $91.06M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.0¢ | 25.0¢ | $36.40K | 143.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40816 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 44646 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |